The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

21 Apr 2016 16:35

RNS Number : 9781V
Amryt Pharma PLC
21 April 2016
 

Standard Form TR-1

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the Central Bank of Ireland)i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Amryt Pharma PLC

2. Reason for the notification (please tick the appropriate box or boxes):

[X] An acquisition or disposal of voting rights

[ ] An acquisition or disposal of financial instruments

[ ] An event changing the breakdown of voting rights

[ ] Other (please specify)iii:

3. Details of person subject to the notification obligationiv :

Name: AXA Investment Managers S.A.

City and country of registered office (if applicable): Paris, France

 

4. Full name of shareholder(s) (if different from 3.)v:

 

5. Date on which the threshold was crossed or reachedvi: 19 April 2016

 

6. Date on which issuer notified: 21 April 2016

 

7. Threshold(s) that is/are crossed or reached: 3%, 4%, 5%, 6%, 7%, 8%, 9%

 

8. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares (total of 9.A)

% of voting rights through financial instruments(total of 9.B.1 + 9.B.2)

Total of both in % (9.A + 9.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

9.90%

0

9.90%

20,625,000

Position of previous notification (if applicable)

NA

NA

NA

NA

 

 

 

9. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii:

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

 

Direct

 

 

Indirect

 

 

Direct

 

 

Indirect

 

GB00BDD1LS57

0

20,625,000

0

9.90%

 

SUBTOTAL A

 

20,625,000

 

9.90%

B 1: Financial Instruments according to Regulation 17(1)(a) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

SUBTOTAL B.1

B 2: Financial Instruments with similar economic effect according to Regulation 17(1)(b) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL B.2

 

10. Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[ ] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

AXA Investment Managers S.A.

9.90%

0

9.90%

11. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

 

 

12. Additional informationxvi:

This notification is made following the placing of Amryt Pharma Plc's ordinary shares respectively on the AIM and ESM Markets dated 19th April 2016.

 

Done at Paris, on 21st April 2016

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFMGZDKMDGVZM
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.